Patrick L. McGeer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Patrick L. McGeer has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
Edith G. McGeer
Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z3
18 shared publicationsAndis Klegeris
Department of Biology, I.K. Barber School of Arts and Sciences, The University of British Columbia Okanagan, Kelowna, B.C., Canada
13 shared publicationsMoonhee Lee
Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada
11 shared publications- Judith Miklossy
International Alzheimer Research Centre, Prevention Alzheimer International Foundation, Martigny-Croix, Switzerland
9 shared publications Claudia Schwab
The ¶Department of Pharmacology, Kyungpook National University School of Medicine, Brain Science and Engineering Institute, Daegu 700422, Korea
6 shared publicationsEdith McGeer
University of British Columbia
6 shared publications
Latest Publications
- 22 October 2012
- Published by Elsevier in Neuroscience
- Vol. 229, 164-175
Neurotoxins released from interferon-gamma-stimulated human astrocytes
- 22 October 2012
- Published by Elsevier in Neuroscience
- Vol. 229, 164-175
Neurotoxins released from interferon-gamma-stimulated human astrocytes
- Open Access
- 1 December 2011
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 286 (48) , 41230-41245
Acidic Fibroblast Growth Factor (FGF) Potentiates Glial-mediated Neurotoxicity by Activating FGFR2 IIIb Protein
- 1 December 2011
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 286 (48) , 41230-41245
Open AccessAcidic Fibroblast Growth Factor (FGF) Potentiates Glial-mediated Neurotoxicity by Activating FGFR2 IIIb Protein
- 11 August 2011
- Published by Springer Nature in Journal of Neuroimmune Pharmacology
- Vol. 7 (1) , 300
Erratum to: Effects of Obovatol on GSH Depleted Glia-Mediated Neurotoxicity and Oxidative Damage
- 11 August 2011
- Published by Springer Nature in Journal of Neuroimmune Pharmacology
- Vol. 7 (1) , 300
Erratum to: Effects of Obovatol on GSH Depleted Glia-Mediated Neurotoxicity and Oxidative Damage
- 28 July 2011
- Published by Springer Nature in Journal of Neuroimmune Pharmacology
- Vol. 7 (1) , 173-186
Effects of Obovatol on GSH Depleted Glia-Mediated Neurotoxicity and Oxidative Damage
Earlier studies indicate that obovatol (OBO), isolated from a medicinal herb Magnolia obovata, has anti-inflammatory and anti-oxidative properties. Depletion of glutathione (GSH) in glial cells with the γ-glutamylcysteine synthase inhibitor D,L-buthionine-S,R-sulfoximine (BSO) is known to produce oxidative stress which, in turn, induces these cells to secrete inflammatory cytokines and other neurotoxic substances. In the present study, we investigated the ability of OBO to protect SH-SY5Y neuroblastoma cells from this effect. Human microglia, astrocytes and their surrogate THP-1 and U373 cell lines were activated by treatment with BSO. Such treatment depleted their intracellular GSH and increased levels of damage to DNA, lipids and proteins (8-OHdG, lipid peroxide, protein carbonyls and 3-nitrotyrosine), and activated the inflammatory pathways P38 MAP kinase and NFκB. These are accompanied by release of proinflammatory factors such as TNFα, IL-6 and nitric oxide. Their conditioned media were toxic to SH-SY5Y cells. All these effects were attenuated by pre-treatment with OBO. Prior treatment of SH-SY5Y cells with OBO also attenuated THP-1 or U373 conditioned media neurotoxicity and also reduced oxidative damage produced by treatment with hydrogen peroxide or BSO. Prior treatment with OBO potentiated survival of SH-SY5Y cells exposed to conditioned medium from BSO-treated THP-1, U373 cells, microglia and astrocytes. The data indicate that OBO could be anti-inflammatory, anti-oxidative and neuroprotective, and be an effective agent for inhibiting pathogenesis in neurological diseases such as Alzheimer disease, Parkinson disease and amyotrophic lateral sclerosis in which glial-mediated neuroinflammation and oxidative stress are thought to contribute to disease progression.
- 28 July 2011
- Published by Springer Nature in Journal of Neuroimmune Pharmacology
- Vol. 7 (1) , 173-186
Effects of Obovatol on GSH Depleted Glia-Mediated Neurotoxicity and Oxidative Damage
Earlier studies indicate that obovatol (OBO), isolated from a medicinal herb Magnolia obovata, has anti-inflammatory and anti-oxidative properties. Depletion of glutathione (GSH) in glial cells with the γ-glutamylcysteine synthase inhibitor D,L-buthionine-S,R-sulfoximine (BSO) is known to produce oxidative stress which, in turn, induces these cells to secrete inflammatory cytokines and other neurotoxic substances. In the present study, we investigated the ability of OBO to protect SH-SY5Y neuroblastoma cells from this effect. Human microglia, astrocytes and their surrogate THP-1 and U373 cell lines were activated by treatment with BSO. Such treatment depleted their intracellular GSH and increased levels of damage to DNA, lipids and proteins (8-OHdG, lipid peroxide, protein carbonyls and 3-nitrotyrosine), and activated the inflammatory pathways P38 MAP kinase and NFκB. These are accompanied by release of proinflammatory factors such as TNFα, IL-6 and nitric oxide. Their conditioned media were toxic to SH-SY5Y cells. All these effects were attenuated by pre-treatment with OBO. Prior treatment of SH-SY5Y cells with OBO also attenuated THP-1 or U373 conditioned media neurotoxicity and also reduced oxidative damage produced by treatment with hydrogen peroxide or BSO. Prior treatment with OBO potentiated survival of SH-SY5Y cells exposed to conditioned medium from BSO-treated THP-1, U373 cells, microglia and astrocytes. The data indicate that OBO could be anti-inflammatory, anti-oxidative and neuroprotective, and be an effective agent for inhibiting pathogenesis in neurological diseases such as Alzheimer disease, Parkinson disease and amyotrophic lateral sclerosis in which glial-mediated neuroinflammation and oxidative stress are thought to contribute to disease progression.
Mechanisms of GABA release from human astrocytes
We have previously demonstrated that human astrocytes are GABAergic cells. Throughout the adult human brain, they express the GABA synthesizing enzyme GAD 67, the GABA metabolizing enzyme GABA‐T, and the GABAA and GABAB receptors. GABA modulates the actions of microglia, indicating an important role for astrocytes beyond that of influencing neurotransmitter function. Here we report on the mechanisms by which astrocytes release GABA. Astrocytes were found to express the mRNA and protein for multiple GABA transporters, and multiple receptors for glutamate, GABA, and glycine. In culture, untreated human astrocytes maintained an intracellular GABA level of 2.32 mM. They exported GABA into the culture medium so that an intracellular‐extracellular gradient of 3.64 fold was reached. Inhibitors of the GABA transporters GAT1, GAT2, and GAT3, significantly reduced this export in a Ca2+‐independent fashion. Intracellular GABA levels were enhanced by treatment with the GABA‐T inhibitors gabaculine or vigabatrin. Treatment with glutamate increased GABA release in a concentration‐dependent fashion. This was partially inhibited by blockers of N‐methyl‐D‐aspartate and kainate receptors. Conversely, glycine and D‐serine, co‐agonists of NMDA receptors, enhanced the GABA release. GABA release was accompanied by an increase in intracellular Ca2+ concentration ([Ca2+]i) and was reduced by adding the Ca2+ chelator, BAPTA‐AM to the medium. These data indicate that astrocytes continuously synthesize GABA and that there are multiple mechanisms which can mediate its release. Each of these may play a role in the physiological functioning of astrocytes.
Mechanisms of GABA release from human astrocytes
We have previously demonstrated that human astrocytes are GABAergic cells. Throughout the adult human brain, they express the GABA synthesizing enzyme GAD 67, the GABA metabolizing enzyme GABA‐T, and the GABAA and GABAB receptors. GABA modulates the actions of microglia, indicating an important role for astrocytes beyond that of influencing neurotransmitter function. Here we report on the mechanisms by which astrocytes release GABA. Astrocytes were found to express the mRNA and protein for multiple GABA transporters, and multiple receptors for glutamate, GABA, and glycine. In culture, untreated human astrocytes maintained an intracellular GABA level of 2.32 mM. They exported GABA into the culture medium so that an intracellular‐extracellular gradient of 3.64 fold was reached. Inhibitors of the GABA transporters GAT1, GAT2, and GAT3, significantly reduced this export in a Ca2+‐independent fashion. Intracellular GABA levels were enhanced by treatment with the GABA‐T inhibitors gabaculine or vigabatrin. Treatment with glutamate increased GABA release in a concentration‐dependent fashion. This was partially inhibited by blockers of N‐methyl‐D‐aspartate and kainate receptors. Conversely, glycine and D‐serine, co‐agonists of NMDA receptors, enhanced the GABA release. GABA release was accompanied by an increase in intracellular Ca2+ concentration ([Ca2+]i) and was reduced by adding the Ca2+ chelator, BAPTA‐AM to the medium. These data indicate that astrocytes continuously synthesize GABA and that there are multiple mechanisms which can mediate its release. Each of these may play a role in the physiological functioning of astrocytes.
- 1 July 2011
- Published by Elsevier in Brain Research
- Vol. 1400, 99-111
Neurotoxic factors released by stimulated human monocytes and THP-1 cells
- 1 July 2011
- Published by Elsevier in Brain Research
- Vol. 1400, 99-111
Neurotoxic factors released by stimulated human monocytes and THP-1 cells
- 20 April 2011
- Published by Elsevier in Progress in Neurobiology
- Vol. 95 (4) , 663-669
The ALS/PDC syndrome of Guam: Potential biomarkers for an enigmatic disorder
- 20 April 2011
- Published by Elsevier in Progress in Neurobiology
- Vol. 95 (4) , 663-669
The ALS/PDC syndrome of Guam: Potential biomarkers for an enigmatic disorder
Proton pump inhibitors reduce interferon‐γ‐induced neurotoxicity and STAT3 phosphorylation of human astrocytes
Proton pump inhibitors (PPIs) are known to possess anti‐inflammatory properties. Inflammatory processes, including astrocytic activation, are implicated in the pathogenesis of different neurodegenerative diseases. Our recent study has indicated that interferon (IFN)‐γ‐induced astrocytic neurotoxicity is mediated, at least in part, by phosphorylation of signal transducer and activator of transcription (STAT) 3. We therefore studied the effects of PPIs on IFN‐γ‐induced neurotoxicity and STAT3 activation of human astrocytes. Both lansoprazole (LPZ) and omeprazole (OPZ) significantly attenuated IFN‐γ‐induced neurotoxicity of human astrocytes and astrocytoma cells. These drugs inhibited IFN‐γ‐induced phosphorylation of STAT 3, but not STAT1. We found that LPZ significantly reduced secretion of IFN‐γ‐inducible T cell α chemoattractant from IFN‐γ‐activated astrocytes. Neither LPZ nor OPZ suppressed expression of intercellular adhesion molecule‐1 by IFN‐γ‐activated astrocytes. These results suggest that PPIs attenuate IFN‐γ‐induced neurotoxicity of human astrocytes through inhibition of the STAT3 signaling pathway. PPIs that possess antineurotoxic properties may be a useful treatment option for Alzheimer's disease and other neuroinflammatory disorders associated with activated astrocytes.
Proton pump inhibitors reduce interferon‐γ‐induced neurotoxicity and STAT3 phosphorylation of human astrocytes
Proton pump inhibitors (PPIs) are known to possess anti‐inflammatory properties. Inflammatory processes, including astrocytic activation, are implicated in the pathogenesis of different neurodegenerative diseases. Our recent study has indicated that interferon (IFN)‐γ‐induced astrocytic neurotoxicity is mediated, at least in part, by phosphorylation of signal transducer and activator of transcription (STAT) 3. We therefore studied the effects of PPIs on IFN‐γ‐induced neurotoxicity and STAT3 activation of human astrocytes. Both lansoprazole (LPZ) and omeprazole (OPZ) significantly attenuated IFN‐γ‐induced neurotoxicity of human astrocytes and astrocytoma cells. These drugs inhibited IFN‐γ‐induced phosphorylation of STAT 3, but not STAT1. We found that LPZ significantly reduced secretion of IFN‐γ‐inducible T cell α chemoattractant from IFN‐γ‐activated astrocytes. Neither LPZ nor OPZ suppressed expression of intercellular adhesion molecule‐1 by IFN‐γ‐activated astrocytes. These results suggest that PPIs attenuate IFN‐γ‐induced neurotoxicity of human astrocytes through inhibition of the STAT3 signaling pathway. PPIs that possess antineurotoxic properties may be a useful treatment option for Alzheimer's disease and other neuroinflammatory disorders associated with activated astrocytes.
- 13 January 2011
- Published by Elsevier in Neurobiology of Aging
- Vol. 33 (7) , 1440-1447
Weak BMAA toxicity compares with that of the dietary supplement beta-alanine
- 13 January 2011
- Published by Elsevier in Neurobiology of Aging
- Vol. 33 (7) , 1440-1447
Weak BMAA toxicity compares with that of the dietary supplement beta-alanine
- Open Access
- 1 January 2011
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 2, 77
History of Innate Immunity in Neurodegenerative Disorders
The foundations of innate immunity in neurodegenerative disorders were first laid by Del Rio Hortega (1919). He identified and named microglia, recognizing them as cells of mesodermal origin. Van Furth in 1969 elaborated the monocyte phagocytic system with microglia as the brain representatives. Validation of these concepts did not occur until 1987 when HLA-DR was identified on activated microglia in a spectrum of neurological disorders. HLA-DR had already been established as a definitive marker of immunocompetent cells of mesodermal origin. It was soon determined that the observed inflammatory reaction was an innate immune response. A rapid expansion of the field took place as other markers of an innate immune response were found that were made by neurons, astrocytes, oligodendroglia, and endothelial cells. The molecules included complement proteins and their regulators, inflammatory cytokines, chemokines, acute phase reactants, prostaglandins, proteases, protease inhibitors, coagulation factors, fibrinolytic factors, anaphylatoxins, integrins, free radical generators, and other unidentified neurotoxins. The Nimmerjahn movies demonstrated that resting microglia were constantly active, sampling the surround, and responding rapidly to brain damage. Ways of reducing the neurotoxic innate immune response and stimulating a healing response continue to be sought as a means for ameliorating the pathology in a spectrum of chronic degenerative disorders.
- 1 January 2011
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 2, 77
Open AccessHistory of Innate Immunity in Neurodegenerative Disorders
The foundations of innate immunity in neurodegenerative disorders were first laid by Del Rio Hortega (1919). He identified and named microglia, recognizing them as cells of mesodermal origin. Van Furth in 1969 elaborated the monocyte phagocytic system with microglia as the brain representatives. Validation of these concepts did not occur until 1987 when HLA-DR was identified on activated microglia in a spectrum of neurological disorders. HLA-DR had already been established as a definitive marker of immunocompetent cells of mesodermal origin. It was soon determined that the observed inflammatory reaction was an innate immune response. A rapid expansion of the field took place as other markers of an innate immune response were found that were made by neurons, astrocytes, oligodendroglia, and endothelial cells. The molecules included complement proteins and their regulators, inflammatory cytokines, chemokines, acute phase reactants, prostaglandins, proteases, protease inhibitors, coagulation factors, fibrinolytic factors, anaphylatoxins, integrins, free radical generators, and other unidentified neurotoxins. The Nimmerjahn movies demonstrated that resting microglia were constantly active, sampling the surround, and responding rapidly to brain damage. Ways of reducing the neurotoxic innate immune response and stimulating a healing response continue to be sought as a means for ameliorating the pathology in a spectrum of chronic degenerative disorders.